ExelixisOvjeren akaunt

@ExelixisInc

Biotechnology company striving to accelerate the development of new medicines for difficult-to-treat cancers. See our guidelines:

Vrijeme pridruživanja: listopad 2010.

Tweetovi

Blokirali ste korisnika/cu @ExelixisInc

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ExelixisInc

  1. 4. velj

    At Exelixis, cancer is our cause. In honor of , see how some of our employees are committed to helping tackle difficult-to-treat-cancers and learn more about the campaign at .

    Poništi
  2. 30. sij

    Caring for a loved one with can require a lot of help. Learn how to facilitate a productive family meeting so no one person is left feeling overwhelmed.

    Poništi
  3. 29. sij

    Our partner applied for regulatory approval of lead therapy for previously treated advanced in Japan. Learn more .

    Poništi
  4. 25. sij

    In the US, approximately 42,000 new cases of were diagnosed in 2019. Learn about the COSMIC-312 clinical trial at Booth 64 and explore more at .

    Poništi
  5. 24. sij

    Explore the COSMIC-021 clinical trial investigating different cancers, including certain GI cancers. See us at and visit our website at .

    Poništi
  6. 24. sij

    Last year approximately 42,000 cases of were diagnosed. Learn more about this disease.

    Poništi
  7. 24. sij

    Data from phase 1/2 CheckMate 040 trial to be presented at now in the Level 2 Ballroom.

    Poništi
  8. 24. sij

    Just announced: Phase 1/2 CheckMate 040 trial results for lead product and immunotherapy combo in advanced : .

    Poništi
  9. 23. sij

    Exelixis is at with our clinical trial for . Explore more at Booth 64 and visit .

    Poništi
  10. 23. sij

    starts today! We look forward to discussing our latest research in gastrointestinal . Visit Exelixis at booth #64 to learn more.

    Poništi
  11. 22. sij

    People who are overweight have a higher risk of developing and . Here are some habits that may help maintain a healthy weight this .

    Poništi
  12. 20. sij

    Today we remember Dr. Martin Luther King Jr. for his commitment to social justice and community service.

    Poništi
  13. 16. sij

    Honored to present at the Healthcare Conference this week and connect with the financial community and industry leaders.

    Poništi
  14. 14. sij

    Investors: to present at the Healthcare Conference today at 4:30 PM PT. Details: .

    Poništi
  15. 13. sij

    We’re excited to welcome the community to San Francisco for the 38th Annual Healthcare Conference this week. We look forward to discussing the future of oncology care.

    Poništi
  16. 12. sij

    Ahead of , we’ve announced our key corporate priorities and anticipated pivotal clinical milestones for the next two years, as well as preliminary Q4/FY’19 financial results and 2020 guidance. Details here: .

    Poništi
  17. 7. sij

    ATTN investors: to present at the Healthcare Conference in San Francisco. Details here: .

    Poništi
  18. 7. sij

    We’re further expanding the cohort in our phase 1b COSMIC-021 trial. Learn more in our latest announcement: .

    Poništi
  19. 1. sij

    ! 2019 was an opportunity for us to reflect on the progress we have made for patients over the past 25 years. We look forward to carrying this momentum forward into 2020.

    Poništi
  20. Considering making New Year’s resolutions? Some of the most common are related to health and may help lower cancer risk. Learn more.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·